Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28662841 | 0.98 | SMN1; SMN2 (0.48) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL4013646 | 0.98 | SMN1; SMN2 (0.48) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL4020930 | 0.98 | SMN1; SMN2 (0.48) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL4022820 | 0.98 | SMN1; SMN2 (0.48) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL4021823 | 0.98 | SMN1; SMN2 (0.48) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL4016268 | 0.98 | SMN1; SMN2 (0.48) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL4018775 | 0.98 | SMN1; SMN2 (0.48) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL4018004 | 0.98 | SMN1; SMN2 (0.48) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL15732 | 0.94 | KEAP1 (0.52) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL2411125 | 0.94 | KEAP1 (0.52) | KEAP1SMN1; SMN2HPGDDUSP3GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1480 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739416-A1 | METHOD OF PURIFICATION | CSL Behring AG (CH) | 2026-05-13 | — | — | EP | claimed |
| EP-4724588-A1 | A METHOD OF ENHANCED SEPARATION OF FULL ADENO-ASSOCIATED VIRUS (AAV) CAPSIDS | Sartorius BIA Separations d.o.o. (SI) | 2026-04-15 | — | — | EP | claimed |
| US-12582670-B2 | Lignin solvation using aqueous biologically compatible buffers | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-03-24 | — | — | US | claimed |
| US-20260047995-A1 | COSMETIC COMPOSITION OF STABILIZED RETINOID BY PH BUFFER | MARY KAY INC (US) | 2026-02-19 | — | — | US | claimed |
| US-20250376770-A1 | NON-TRIAZOLE YELLOW METAL CORROSION INHIBITOR COMPOSITIONS AND METHODS OF TREATMENT | CHEMTREAT, INC. (US) | 2025-12-11 | — | — | US | claimed |
| US-20250312297-A1 | REDUCTION OF HEALTHCARE RESOURCE UTILIZATION BY PATIENTS TREATED WITH INTRANASALLY-ADMINISTERED METOCLOPRAMIDE | EVOKE PHARMA, INC. | 2025-10-09 | — | — | US | claimed |
| US-20250302777-A1 | METHODS FOR TREATING GASTROPARESIS | EVOKE PHARMA, INC. | 2025-10-02 | — | — | US | claimed |
| US-12421654-B2 | Method for manufacturing mycelium mat into leather by using pH-controlled tannic acid | MYCEL INC. (KR) | 2025-09-23 | — | — | US | claimed |
| US-20250277149-A1 | ETCHING COMPOSITION AND METHOD FOR MANUFACTURING SEMICONDUCTOR DEVICE USING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-09-04 | — | — | US | claimed |
| US-20250228803-A1 | NASAL FORMULATIONS OF METOCLOPRAMIDE | EVOKE PHARMA, INC. | 2025-07-17 | — | — | US | claimed |
| US-20020183293-A1 | Administering durg comprising formoterol, or a derivative thereof and asteroidal anti-inflammatory agent, or a derivative in a pharmacologically suitable fluid, wherein the drug formulation is stable during long term storage | MYLAN PHARMACEUTICALS, INC. | 2002-12-05 | — | — | US | claimed |
| EP-1255576-A1 | MINERAL-POLYMER HYBRID COMPOSITION | Biosyntech Canada Inc. (CA) | 2002-11-13 | — | — | EP | claimed |
| WO-2002083113-A2 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL AND A STEROID SUCH AS E.G. BUDESONIDE OR FLUTICASONE FOR DELIVERY INTO THE LUNGS VIA NEBULIZATION | DEY, L.P. (US) | 2002-10-24 | — | — | WO | claimed |
| WO-2002083136-A1 | THERAPEUTIC COMPOSITIONS COMPRISING AMINO SULFONIC ACIDS AND THEIR USES | PROCESS & INDUSTRIAL DESIGN CONSULTANTS LTD (IE) | 2002-10-24 | — | — | WO | claimed |
| WO-2002083079-A2 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL FOR DELIVERY TO THE LUNGS VIA NEBULIZATION | DEY, L.P. (US) | 2002-10-24 | — | — | WO | claimed |
| US-20020151598-A1 | Formoterol, or a derivative; long term storage stability | MYLAN TECHNOLOGIES, INC. | 2002-10-17 | — | — | US | claimed |
| US-20020151597-A1 | Formoterol, or a derivative; long term storage stability | DEY L.P. | 2002-10-17 | — | — | US | claimed |
| EP-1229940-A1 | TEMPERATURE-CONTROLLED AND PH-DEPENDANT SELF-GELLING BIOPOLYMERIC AQUEOUS SOLUTION | BIO SYNTECH CANADA INC. (CA) | 2002-08-14 | — | — | EP | claimed |
| WO-2001041822-A1 | MINERAL-POLYMER HYBRID COMPOSITION | BIOSYNTECH CANADA INC. (CA) | 2001-06-14 | — | — | WO | claimed |
| WO-2001036000-A1 | TEMPERATURE-CONTROLLED AND PH-DEPENDANT SELF-GELLING BIOPOLYMERIC AQUEOUS SOLUTION | BIO SYNTECH CANADA, INC. (CA) | 2001-05-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260047995-A1 | COSMETIC COMPOSITION OF STABILIZED RETINOID BY PH BUFFER | RARB, RARA, RARG | KEAP1 2688/4885SMN1; SMN2 2898/4885HPGD 661/4885 |
| US-20020151597-A1 | Formoterol, or a derivative; long term storage stability | ADRB2, ADRA2C, ADRA2A | KEAP1 628/4885SMN1; SMN2 136/4885HPGD 199/4885 |
| US-20250228803-A1 | NASAL FORMULATIONS OF METOCLOPRAMIDE | MC2R, MTNR1B, MC4R | KEAP1 2983/4885SMN1; SMN2 523/4885HPGD 718/4885 |
| US-12582670-B2 | Lignin solvation using aqueous biologically compatible buffers | HCLS1, ASNS, EPAS1 | KEAP1 338/4885SMN1; SMN2 3588/4885HPGD 1793/4885 |
| US-20020183293-A1 | Administering durg comprising formoterol, or a derivative thereof and asteroidal anti-inflammatory agent, or a derivative in a pharmacologically suitable fluid, wherein the drug formulation is stable during long term storage | AREG, IL5, IL17A | KEAP1 1978/4885SMN1; SMN2 410/4885HPGD 134/4885 |
| US-20020151598-A1 | Formoterol, or a derivative; long term storage stability | ADRB2, ADRA2C, ADRA2A | KEAP1 628/4885SMN1; SMN2 136/4885HPGD 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.